Targeting inflammation and fibrosis from the start – can belumosudil improve long-term outcomes in chronic GvHD?
Friday, October 25th, 2024
10:20-11:50
This Sanofi-sponsored educational symposium will shine a light on the role of inflammation and fibrosis in chronic GvHD, the current treatment landscape, and the impact of chronic GvHD on patient quality of life.
Moderator: Nicolaus Kröger (Germany)
| AGENDA | |
|---|---|
| 10:20–10:25 | Welcome and introduction Nicolaus Kröger (Chair), Germany |
| 10:25–10:40 | The challenges of fibrosis and inflammation in cGvHD Robert Zeiser, Germany |
| 10:40–10:55 | Exploring the cGvHD treatment landscape Corey Cutler, US |
| 10:55–11:10 | The impact of cGvHD on quality of life Zinaida Perić, Croatia |
| 11:10–11:45 |
Applying the data to clinical practice: Patient case study
Matthias Fante, Germany Discussion: How can we improve patient outcomes through early intervention in cGvHD?
All (moderated by Chair) |
| 11:45–11:50 | Closing remarks Nicolaus Kröger (Chair) |
